论文部分内容阅读
目的评价食管癌超分割放射治疗的疗效及放射反应。方法100例食管癌随机分为2个组:常规分割放射治疗组50例,1次/a,2Gy/次,5次/周,总剂量66Gy/33F,6.6W;超分割放射治疗组50例,2次/a,1.15Gy/次,间隔6d以上,10次/周,总剂量75.9Gy/66F,6.6W。结果两组的放射毒性发生率差异无统计学意义(P>0.05)。超分割组和常规分割组的2,4,6,8年局控率分别为57.1%,52.6%,47.9%,42.2%和34.6%,29.2%,25.4%,21.6%;两个组比较差异有统计学意义(χ2=6.452,P<0.05)。超分割组和常规分割组的2,4,6,8年生存率分别为30.1%,24.2%,22.8%,18.5%和22.4%,18.5%,14.6%,12.1%;两个组比较差异无统计学意义(χ2=3.174,P>0.05)。结论食管癌超分割放射治疗能提高局控率,放射毒性无明显加重。
Objective To evaluate the efficacy and radiation response of esophageal cancer hyper-fractionated radiotherapy. Methods 100 cases of esophageal cancer were randomly divided into 2 groups: 50 cases in conventional radiotherapy group, once / a, 2Gy / time, 5 times / week, total dose 66Gy / 33F, 6.6W; , 2 times / a, 1.15Gy / times, more than 6d intervals, 10 times / week, the total dose of 75.9Gy / 66F, 6.6W. Results There was no significant difference in the incidence of radiation toxicity between the two groups (P> 0.05). The rates of 2, 4, 6 and 8 years of superfractionation and conventional subgroups were 57.1%, 52.6%, 47.9%, 42.2% and 34.6%, 29.2%, 25.4% and 21.6% respectively. The differences between the two groups There was statistical significance (χ2 = 6.452, P <0.05). The 2-year, 4-year, 6-year and 8-year survival rates were 30.1%, 24.2%, 22.8%, 18.5% and 22.4%, 18.5%, 14.6% and 12.1% in the superfraction group and the conventional group respectively. There was no significant difference between the two groups Statistical significance (χ2 = 3.174, P> 0.05). Conclusion Esophageal cancer hyperfractionated radiotherapy can improve the rate of local control, no significant increase in radiotoxicity.